Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapyTraumatic ...
Hosted on MSN
Acurx signals ongoing cost controls and new trial funding avenues while advancing ibezapolstat clinical program
Luci explained that efforts to secure partnerships, including with government agencies, are ongoing and "will certainly slip into 2026, given the dynamics that are going on in Washington," but ...
At this year's conference, TransCelerate and representatives from its member companies, including Amgen, Merck, and Pfizer, will participate in seven sessions addressing topics such as data collection ...
Hosted on MSN
Acurx signals progress in Phase 3 ibezapolstat program with $12M credit line following regulatory alignment
David Luci, President and CEO, highlighted several significant developments, including the closing of a $2.5 million registered direct offering and the receipt of positive regulatory guidance from the ...
Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion TreatmentSarasota, Fla., Feb. 02, 2026 (GLOBE ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today reported that clinical trial site activation for enrollment is underway for the company’s Phase 3 program evaluating zaltenibart in ...
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (TransCode), a clinical stage company pioneering immuno-oncology and RNA therapeutics ...
HOUSTON, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (NASDAQ: PSTV) (the "Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals ...
VYNE Therapeutics Inc. has provided an update on its clinical program for VYN202, an oral small molecule BET inhibitor aimed at treating moderate-to-severe plaque psoriasis. Following a clinical hold ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results